About Forus
Leadership
Values
Latest News
XPOVIO® Now Funded in Saskatchewan
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Saskatchewan as of September 1st. Please see the following link for full funding criteria: Drug Formulary (saskcancer.ca). We are excited about this important milestone for...
XPOVIO® Now Funded in Alberta
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Alberta as of June 5, 2023. Please see the following link for full funding criteria: AHS Outpatient Cancer Drug Benefit Program 2023-06-05 (albertahealthservices.ca). We are...
FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome on May 27th, 2023
(Saint-lgnace-de-Stanbridge, Quebec) May 27th, 2023 – FORUS Therapeutics was a proud sponsor of the 11th Edition of the Défi Cyclo-Myélome. The Défi Cyclo-Myélome provides support to Dr. Richard LeBlanc, holder of the Université de Montréal Myeloma Canada Chair on...
Contact Us
Mailing Address:
FORUS Therapeutics Inc.
200 North Service Road West, Suite 129
Oakville, Ontario, L6M 2Y1
Phone: 1-877-359-9595
Fax: 1-877-359-9590
Patient Support:
Phone: 1-833-4YOUPSP (1-833-496-8777)
Fax: 1-833-4YOUFAX (1-833-496-8329)
Product Support:
Phone: 1-866-542-7500
Fax: 1-866-542-1100
Do not use this form to report adverse events. Adverse events can be reported at 1-866-542-7500.